Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitomycin sustained release - UroGen Pharma

Next Previous
Drug Profile

Mitomycin sustained release - UroGen Pharma

Alternative Names: Jelmyto; MitoGel®; Mitomycin 0.18% gel; Mitomycin 0.4% gel; Mitomycin C mixed with TC Gel; Mitomycin C mixed with TC-3 gel; MMC gel; UGN 101; UGN 102; UGN-103; UGN-104; VesiGel™; Zusduri

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraCoat
  • Developer Neopharm Ltd; UroGen Pharma
  • Class Amines; Antiglaucomas; Antineoplastics; Aza compounds; Aziridines; Carbamates; Cytostatic antibiotics; Eye disorder therapies; Heterocyclic compounds with 4 or more rings; Indoles; Mitomycins; Pyrroles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Urogenital cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Bladder cancer; Urogenital cancer

Most Recent Events

  • 16 Jun 2025 Launched for Bladder cancer (Recurrent) in USA (Intravesicular)
  • 12 Jun 2025 Registered for Bladder cancer (Recurrent) in USA (Intravesicular)
  • 12 Jun 2025 Updated efficacy and adverse events data from the phase III trial in Bladder cancer released by UroGen Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top